Summary & Overview
Adrenal and Pituitary Procedures without CC/MCC: Inpatient Reimbursement Overview
DRG 615 encompasses inpatient admissions for adrenal and pituitary procedures performed without a Complication or Comorbidity or Major Complication or Comorbidity; it covers surgical treatments like adrenalectomy and transsphenoidal pituitary operations. Correct assignment matters for inpatient reimbursement because grouping into this Diagnosis-Related Group versus higher-severity groups affects Medicare payment rates tied to resource use.
DRG 615 Overview
DRG 615 covers inpatient admissions for adrenal and pituitary gland procedures without a Complication or Comorbidity or Major Complication or Comorbidity. This category includes surgical interventions such as adrenalectomy and transsphenoidal pituitary surgery when no additional coded CC or MCC is present. It matters for Medicare payment because the presence or absence of Complication or Comorbidity and Major Complication or Comorbidity affects relative payment weight and reimbursement classification. Accurate coding of procedures and comorbid conditions determines assignment to this Diagnosis-Related Group and thus influences Medicare inpatient payment.
Clinical Trials
- Perioperative outcomes and surgical technique trials focusing on minimally invasive versus open approaches for adrenalectomies and transsphenoidal pituitary surgeries: these studies enroll patients scheduled for adrenal or pituitary procedures to compare intraoperative metrics (blood loss, operative time), complication rates, and short-term length of stay between approaches and technical variations. They address acute procedural care and are relevant to surgeons, hospital administrators, and payers because differences in complications and LOS directly affect inpatient resource utilization, cost, and DRG-related reimbursement.
- Comparative effectiveness studies of perioperative endocrine management and complication prevention in patients with functional adrenal or pituitary tumors: these trials examine protocols for preoperative optimization (e.g., glucocorticoid or mineralocorticoid management, blood pressure control, and perioperative hormone replacement strategies) and evaluate rates of adrenal crisis, electrolyte disturbances, and readmissions. The patient population includes hormonally active tumor cases and medically complex patients; findings inform best practices that reduce perioperative morbidity and downstream costs important for clinicians and payers.
- Post-discharge outcomes and quality-of-life cohort studies assessing long-term endocrine recovery, recurrent disease surveillance, and healthcare utilization after adrenal or pituitary surgery: these observational or registry-based studies follow patients after discharge to measure endocrine function restoration, need for lifelong hormone replacement, recurrence rates, outpatient visit frequency, and subsequent hospital readmissions. This stage-of-care research is relevant to providers and payers because it captures longer-term resource use and outcomes that influence total cost of care, readmission penalties, and decisions about follow-up intensity and care coordination.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.